Pneumoconiosis Global Market Report 2025

The pneumoconiosis market size has grown steadily in recent years. It will grow from $1.43 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. Growth during the historic period was driven by a surge in occupational lung conditions, expanding industrial activities in developing nations, increased focus on occupational health, stricter regulatory frameworks concerning dust exposure, and the expansion of coal and silica mining industries.

The pneumoconiosis market size is expected to see steady growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Factors contributing to this forecasted growth include a rise in the aging population, broader use of cutting-edge imaging and diagnostic tools, escalating healthcare funding, enhanced research initiatives in respiratory diseases, and a rise in legal and compensation-related cases. Noteworthy trends expected in this period include improvements in imaging techniques, the use of AI in radiological assessments, adoption of remote patient monitoring solutions, innovations in wearable respiratory technologies, and enhanced pulmonary drug delivery platforms.

The rising exposure to asbestos is expected to propel the growth of the pneumoconiosis market going forward. Asbestos exposure occurs when a person inhales or comes into contact with asbestos fibers, potentially causing severe health conditions like asbestosis, mesothelioma, and lung cancer. Asbestos exposure is increasing as renovations and demolitions of old buildings release harmful fibers into the air, raising inhalation risks. Inhalation of asbestos fibers can lead to pneumoconiosis, as the fibers become lodged in the lungs and cause persistent inflammation. This ongoing irritation results in lung scarring (fibrosis), which gradually impairs breathing and overall lung function. For instance, in July 2024, according to the report published by the UK Asbestos Training Association (UKATA), a UK-based training and awareness organization, over 5,000 asbestos-related disease deaths occur annually in the UK, with 493 asbestosis-related deaths in 2022, while over 70% of these deaths are in individuals aged over 75. Therefore, the increasing exposure to asbestos is driving the growth of the pneumoconiosis market.

Major companies operating in the pneumoconiosis market are focused on developing advanced solutions, such as clinical trials for pneumoconiosis medication to improve treatment efficacy, slow disease progression, and enhance patient outcomes. A clinical trial for pneumoconiosis medication is a research process that tests a new drug’s safety, effectiveness, and side effects in managing the disease. It involves human participants and progresses through phases to determine its suitability for broader medical use. For instance, in June 2022, Beijing Continent Pharmaceutical Co. Ltd., a China-based pharmaceutical company, announced the enrollment of the first subject in a Phase III clinical trial for Pirfenidone Capsules (F647) aimed at treating pneumoconiosis, a serious occupational lung disease caused by inhalation of dust leading to fibrosis. Pirfenidone, an oral small-molecule drug that inhibits collagen synthesis and regulates fibrotic cytokines such as TGF-β, is already a key product for the company, and this trial represents its fifth therapeutic indication. The Phase III study seeks to confirm the efficacy and safety of F647 for pneumoconiosis, which remains the most common occupational disease in China.

In January 2025, ICV Partners LLC, a US-based investment firm and capital partner to lower middle market companies, acquired Environmental Remedies LLC (ERI) for an undisclosed amount. The acquisition aims to accelerate ERI’s growth through infrastructure expansion, development of its leadership team, and enhancement of operational capabilities, leveraging ICV’s experience with family-owned and founder-led companies. Environmental Remedies LLC (ERI) is a US-based provider of high-quality asbestos abatement services.

Major players in the pneumoconiosis market are AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk, Koninklijke Philips NV, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals Inc., Inogen, GNI Group Ltd., and DRIVE MEDICAL GMBH & CO. KG.

North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumoconiosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumoconiosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pneumoconiosis refers to a group of lung disorders that arise from extended exposure to hazardous dust in occupational settings, particularly within manufacturing sectors. These inhaled particles accumulate in the lungs, causing inflammation, fibrotic tissue changes, and reduced pulmonary function. Timely diagnosis is essential to slow disease advancement, improve patient outcomes, and enforce workplace safety measures to limit exposure.

The primary forms of pneumoconiosis include asbestosis, silicosis, coal workers' pneumoconiosis, and berylliosis. Asbestosis is a long-term lung condition triggered by sustained inhalation of asbestos fibers, which results in lung irritation, scarring, and progressively worsening breathing problems. It is identified through diagnostic methods such as chest X-rays, CT scans, pulmonary function tests, and more, and is managed through various treatments like medications, oxygen supplementation, pulmonary rehabilitation, among others. The disease is treated and distributed via different channels, including hospital pharmacies, retail outlets, online pharmacies, and others, and utilized across diverse healthcare settings such as hospitals, specialty clinics, diagnostic facilities, and more.

The pneumoconiosis market research report is one of a series of new reports that provides pneumoconiosis market statistics, including the pneumoconiosis industry global market size, regional shares, competitors with the pneumoconiosis market share, detailed pneumoconiosis market segments, market trends, opportunities, and any further data you may need to thrive in the pneumoconiosis industry. This pneumoconiosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumoconiosis market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, medication management, patient education and counseling, and workplace exposure assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumoconiosis market also includes sales of corticosteroids, protective respiratory gear, and pulmonary rehabilitation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.